Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis
Номер патента: EP4373489A1
Опубликовано: 29-05-2024
Автор(ы): Christopher Farady, Ewa GATLIK, Laura COLEMAN, Matthias Schieker
Принадлежит: NOVARTIS AG
Опубликовано: 29-05-2024
Автор(ы): Christopher Farady, Ewa GATLIK, Laura COLEMAN, Matthias Schieker
Принадлежит: NOVARTIS AG
Реферат: The present disclosure relates to the field of pharmacy, particularly to an NLRP3 inhibitor for use in the treatment of osteoarthritis. The disclosure also relates to an NLRP3 inhibitor or a pharmaceutical combination comprising an NLRP3 inhibitor, and at least one further therapeutic agent, for use in the treatment of osteoarthritis; to a method for the treatment of osteoarthritis that involves administering an NLRP3 inhibitor or the combination; and to the use of an NLRP3 inhibitor or the combination for the manufacture of a medicament for the treatment of osteoarthritis.
Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis
Номер патента: CA3224774A1. Автор: Matthias Schieker,Christopher Farady,Ewa GATLIK,Laura COLEMAN. Владелец: NOVARTIS AG. Дата публикации: 2023-01-26.